LLY
Eli Lilly and Company
LLY has the edge over MDXG overall, supported by stronger fundamentals and stronger modeled upside.
MDXG
MiMedx Group, Inc.
MDXG trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDXG Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
MDXG's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MDXG PE Valuation
MDXG has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over MDXG on the outlook, with more favorable revenue expectations.
MDXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MDXG's earnings to grow and its profitability to improve, but its revenue to decline.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MDXG on earnings quality, reporting a profit while its opponent remains loss making.
MDXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.07 | — |
| Q3 2026 | -$0.13 | -148% |
| Q2 2026 | $0.04 | -81% |
| Q1 2026 | $0.20 | -26% |
| Q4 2025 | $0.32 | +14% |
| Q3 2025 | $0.27 | -55% |
| Q2 2025 | $0.21 | -66% |
| Q1 2025 | $0.27 | -45% |
| Q4 2024 | $0.28 | -24% |
MDXG has swung to a loss: it lost $0.13 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MDXG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MDXG on profitability, with a higher operating margin.
MDXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | -45% |
| Q2 2026 | $64.4M | -35% |
| Q1 2026 | $59M | -33% |
| Q4 2025 | $118.1M | +27% |
| Q3 2025 | $113.7M | +35% |
| Q2 2025 | $98.6M | +13% |
| Q1 2025 | $88.2M | +4.1% |
| Q4 2024 | $92.9M | +7% |
MDXG's revenue is shrinking: $62M last quarter, down 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -19% | -38 points |
| Q2 2026 | -29% | -41 points |
| Q1 2026 | -27% | -37 points |
| Q4 2025 | 18% | +6 points |
| Q3 2025 | 20% | +6.2 points |
| Q2 2025 | 13% | -14 points |
| Q1 2025 | 9.3% | -6.2 points |
| Q4 2024 | 12% | -19 points |
MDXG's operating margin was −19% last quarter, down 38 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MDXG on cash flow, with more consistent year-over-year improvement.
MDXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.9M | -87% |
| Q2 2026 | -$10M | -169% |
| Q1 2026 | $1.9M | -65% |
| Q4 2025 | $25M | +33% |
| Q3 2025 | $29.3M | +49% |
| Q2 2025 | $14.4M | -34% |
| Q1 2025 | $5.3M | -11% |
| Q4 2024 | $18.8M | +91% |
MDXG generated $21M in free cash flow over the past year, down 69% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MDXG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -1.9M shares |
| 1 year | -2.6% | -3.8M shares |
| 3 years | +22% | +26.5M shares |
| 5 years | +32% | +35.1M shares |
| Available history | +36% | +38.9M shares |
MDXG has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $304,000 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MDXG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -10.1x | Net Cash |
| Q1 2026 | -3.4x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -0.9x | Net Cash |
MDXG has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MDXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.1 | Oversold |
| Stochastic | 15.2 | Oversold |
MDXG's weekly RSI is 28 (oversold) and its Stochastic is 15 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over MDXG on valuation relative to its sector.
MDXG PE vs Healthcare Sector
| Metric | MDXG | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 92 | 29 | 63 pts above |
MDXG has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MDXG on trend strength, trading above more of its moving averages.
MDXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.09 | 21% below |
| 20 week MA | $4.24 | 24% below |
| 50 week MA | $4.52 | 28% below |
| 100 week MA | $5.92 | 45% below |
| 200 week MA | $6.31 | 49% below |
MDXG is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MDXG on returns for 2026, with the stronger performance.
MDXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.25 | $9.40 | +30% |
| 2021 | $9.40 | $6.49 | -31% |
| 2022 | $6.49 | $2.77 | -57% |
| 2023 | $2.77 | $8.77 | +217% |
| 2024 | $8.77 | $9.42 | +7.4% |
| 2025 | $9.42 | $6.90 | -27% |
| 2026 YTD | $6.90 | $3.24 | -53% |
MDXG's yearly returns have swung widely, from +217% in 2023 to −57% in 2022. It's down 53% so far in 2026.